The winners of the Natural Light - International Design Competition have now been chosen from the 172 impressive Natural Light Lamp designs submitted from 65 countries around the world. The winners are two very talented Argentinian Industrial Design students, Ms. Mariana Arando and Mr. Luca Fondello, both from the University of Buenos Aires, Argentina. The production phase of the winning design for the Natural Light Lamp will begin shortly, followed next year by shipment of the lamps to three African countries without access to electricity.
Last year, the VELUX Group and Little Sun joined forces to launch the Natural Light – International Design Competition, which challenged design students around the world to create a design for a solar lamp which would help to bring clean, reliable, affordable light to some of the 1.2 billion people worldwide living without electricity. Now the jury has voted and decided on the winning solar lamp design by two Industrial Design students from the University of Buenos Aires in Argentina.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7533451-velux-winner-announcement-natural-light/
Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun’s innovative “first-in-class” anti-heart failure drug, Neucardin™.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61677-zensun-completes-clinical-trials-of-neucardin-treatment-of-heart-failure
Today Concentrix Corporation, a wholly-owned subsidiary of SYNNEX Corporation (NYSE: SNX), announced the addition of 19 delivery locations, across 13 countries, completing the second phase of the acquisition of IBM's global customer care and industry process services business. With over 95% of the acquisition completed, Concentrix continues to advance its position as a leader in the customer care and industry process services market, with over 45,000 employees delivering high value services.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7146451-concentrix-completes-2nd-phase-of-ibm-customer-care-business-acquisition
Volkswagen startet 30 Jahre nach seinem Markteintritt in China in eine Phase nachhaltigen Wachstums. Im Zuge des Ausbaus der Fertigungskapazitäten investieren die beiden chinesischen Joint-Ventures des Volkswagen Konzerns bis 2015 mehr als zwei Drittel von insgesamt 9,8 Milliarden Euro in hocheffiziente Produkte. Der für China zuständige Vorstand der Volkswagen Aktiengesellschaft Prof. Dr. Jochem Heizmann, präzisierte am Vortag der Auto Shanghai 2013 die auf den chinesischen Markt zugeschnittene Elektromobilitäts-Strategie. Es sei geplant, von 2014/2015 an Fahrzeuge mit elektrifiziertem Antrieb anzubieten, die zum Teil lokal produziert werden. Bereits 26 Modelle des Konzerns sind von staatlicher Seite als besonders energiesparend und umweltschonend anerkannt worden. Volkswagen habe den verbrauch seiner in China derzeit mehr als 70 Modelle umfassenden Flotte zwischen 2005 und 2010 um 20 Prozent reduziert und werde ihn bis 2015 um weitere 11 Prozent senken.
Kubota Tractor Corporation has announced the availability of its second phase of all-new Kubota Hay Tools in dealerships nationwide. The recently expanded hay tools line brings to market new round balers and turntable bale wrappers; side-mounted and trailed disc mowers; trailed mower conditioners; and a complete range of rotary tedders and rakes.
The new machinery is designed specifically for the U.S. market to further expand Kubota's presence in the larger agricultural product market. "With our extended line of hay tools, we are building on the success of our well-received initial hay tools launch last year and responding to outstanding dealer and customer demand for more high-performing implements from Kubota," said Dave Palmer, senior product manager of Kubota hay tools. "Kubota understands that our customers depend on our equipment's productivity and by providing the right tools, we always deliver. Kubota's hay tools are performance-matched to ideally complement our M-Series tractors and deliver a more comprehensive line of haying solutions for our customers' needs."
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7443251-kubota-tractor-hay-tools/
Typical bathroom products like shampoo bottles, toilet paper rolls and toothpaste boxes are significantly less likely to be recycled than kitchen products according to survey results released today by the Ad Council. Nonprofits Keep America Beautiful and the Ad Council have joined with Unilever to expand the conversation around recycling and motivate more Americans to remember to recycle in the bathroom by launching a new phase of the national, award-winning “I Want To Be Recycled” communications campaign, featuring a brand new series of broadcast and digital PSAs.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7444951-keep-america-beautiful-recycle/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
After analyzing millions of Internet visits and interviewing scores of consumers, Brookdale Senior Living has built a new website based on fresh insights into what’s most important to families searching for senior care. The first phase, which is a $4 million investment, went live on brookdale.com mid-August.
“With Brookdale’s website attracting more than 500,000 visits every month, it’s imperative to make it as useful to consumers as possible,” said David Cygan, Brookdale’s senior vice president of marketing. “As the nation’s largest senior living provider, we know our website is a primary source of information, with many people coming to us first as they embark on this journey,” Cygan said. “It’s important that we offer substantive resources that make it easier to find help in evaluating senior care options.” More than 80 percent of adult children turn to the Internet when they look for care for an aging parent, according to the company’s research.
To view the multimedia release go to:
http://www.multivu.com/players/English/7722159-new-brookdale-senior-living-website/
NRG Energy, Inc. (NYSE:NRG), NRG Yield, Inc. (NYSE: NYLD), and SunPower Corp. (NASDAQ: SPWR) today announced the completion of the final phase of the California Valley Solar Ranch (CVSR) photovoltaic (PV) generating facility in San Luis Obispo County, California, bringing total electric generating capacity of the plant up to 250 megawatts (AC). NRG acquired CVSR from SunPower in 2011, and the project is jointly owned by NRG Yield (48.95%). CVSR is one of the world’s largest operating solar PV power plants and will sell its electricity to Pacific Gas & Electric under two long-term power purchase agreements.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64118-sunpower-nrg-energy-begin-commercial-operations-250-mw-calif-solar-ranch
Online Registration Guidline
ACRI is specialized in providing Clinical Research Courses like Pg Diploma in clinical CDM and SAS course with guarantee internship in leading CRO’S & 100% Placement.
Reach us at:
Avigna Clinical Research Institute:-
No.33,3rd Floor,15th Cross,
2nd Phase,J.P.Nagar,100ft Ring Road,
Bangalore-560078
080-26588910 / 91-9741600499
http://www.acriindia.com
info@acriindia.com
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
